Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jul;150(1):226-36.
doi: 10.1016/j.chest.2016.01.007. Epub 2016 Jan 22.

Persistent Challenges in Pediatric Pulmonary Hypertension

Rachel K Hopper  1 , Steven H Abman  2 , D Dunbar Ivy  2
Affiliations
Review

Persistent Challenges in Pediatric Pulmonary Hypertension

Rachel K Hopper et al. Chest. 2016 Jul.

Abstract

Pulmonary hypertension and related pulmonary vascular diseases cause significant morbidities and high mortality and present many unique challenges toward improving outcomes in neonates, infants, and children. Differences between pediatric and adult disease are reflected in controversies regarding etiologies, classification, epidemiology, diagnostic evaluations, and therapeutic interventions. This brief review highlights several key topics reflecting recent advances in the field and identifies persistent gaps in our understanding of clinical pediatric pulmonary hypertension.

Keywords: pediatric cardiology; pediatric pulmonary; pulmonary hypertension.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Venn diagram illustrating the heterogeneity and multifactorial elements in pediatric pulmonary hypertensive vascular disease. Insults on the growing lung may be due to ventilator-induced lug injury. Developmental abnormalities may include conditions such as bronchopulmonary dysplasia. Examples of multifactorial conditions may include aspiration or congenital heart disease.
Figure 2
Figure 2
A, Postmortem lung pathology from a normal lung at 6 months of age and lung from a patient with CDH at 7 months of age. CDH lung shows alveolar simplification (top) and muscularization of the small pulmonary arteries (arrows, bottom). Images courtesy Marcus Davey, PhD. B, Muscular hypertrophy and intimal hyperplasia in pulmonary arteries from lung biopsy specimens of two pediatric patients with CDH and PH. Aw, airway; PA, pulmonary artery.
Figure 3
Figure 3
Adapted treatment algorithm for idiopathic or heritable pediatric pulmonary arterial hypertension. CCB = calcium channel blocker.
Figure 4
Figure 4
Kaplan-Meier survival curve in 77 children with PH who were treated with chronic intravenous prostacyclin analogues (including epoprostenol or treprostinil, and those who transitioned from epoprostenol to treprostinil). The shaded areas depict the 95% CI. Transplant-free 5-year survival was 70% (95% CI, 56%-80%).
See this image and copyright information in PMC

References

    1. Maxwell B.G., Nies M.K., Ajuba-Iwuji C.C., Coulson J.D., Romer L.H. Trends in hospitalization for pediatric pulmonary hypertension. Pediatrics. 2015;136(2):241–250. - PubMed
    1. Frank D.B., Crystal M.A., Morales D.L.S. Trends in pediatric pulmonary hypertension-related hospitalizations in the United States from 2000-2009. Pulm Circ. 2015;5(2):339–348. - PMC - PubMed
    1. Abman S.H., Hansmann G., Archer S.L. Pediatric pulmonary hypertension guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015;132(21):2037–2099. - PubMed
    1. Jain A., McNamara P.J. Persistent pulmonary hypertension of the newborn: advances in diagnosis and treatment. Semin Fetal Neonatal Med. 2015;20(4):262–271. - PubMed
    1. Simonneau G., Gatzoulis M.A., Adatia I. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25):D34–D41. - PubMed

Publication types